Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PECS II vs TPVB vs GA for Breast Fibroma
NCT06608810Completed
- Sponsor
- Inner Mongolia Baogang Hospital
- Start
- Jul 2023
- Primary completion
- May 2024
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine hydrochloride liposomal suspension injection in adenofibroma (3 arms), sponsored by Inner Mongolia Baogang Hospital. Primary endpoint: Visual Analog Scale at 1 week. Started Jul 2023; status: completed.
02
Drugs
ropivacaine hydrochloride liposomal suspension injection
03
Conditions
adenofibroma
Beyond the preview
Go deeper on NCT06608810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06608810.